RedHill Biopharma's antibiotic succeeds in late-stage study

Israel-based RedHill Biopharma Ltd said on Monday its combination antibiotic met the main goal of a late-stage study testing the drug in patients with a type of bacterial infection that affects the stomach and small intestine.

Can better cancer care lower company's health costs?

When companies try to tackle rising healthcare costs, shifting more of the burden to employees is increasingly the strategy of choice.

South Africa court paves way for class action against Tiger Brands

A South African court on Monday granted a class action certificate to victims of listeriosis, paving the way for them to claim against Tiger Brands after the world's largest ever outbreak claimed more than 200 lives in the country.

Norway biotech Ultimovacs plans IPO to develop cancer drug

Norway's Ultimovacs plans to raise around 700 million Norwegian crowns ($82 million) in an initial public offering in early 2019 to help fund the development of its immunotherapy cancer drug.

Measles threat looms in Philippines as trust in vaccines declines: health officials

Health experts on Monday warned against a possible outbreak of measles in the Philippines, as a disease long under control is fueled by patchy immunization programs and declining trust in vaccines.

Dutch firm argenx, J&J affiliate to collaborate on cancer therapy

Netherlands-based biopharmaceutical company argenx SE said it signed a deal with Cilag GmbH International, an affiliate of Johnson & Johnson's Janssen Pharmaceutical Companies unit, to develop its Cusatuzumab drug in certain types of cancer.

China reports new African swine fever outbreak on farm in Beijing with nearly 10,000 pigs

China's agriculture ministry said on Monday it has confirmed a new African swine fever outbreak on a farm in capital city Beijing, as well as two other outbreaks in Shaanxi and Heilongjiang provinces.

Novartis SMA treatment could get FDA approval in May

Novartis's gene therapy for spinal muscular atrophy (SMA) could be approved in May 2019 after the U.S. Food and Drug Administration agreed to an accelerated review of the Swiss drugmaker's treatment.

High-cost Gilead cell therapy proves durable for some lymphoma patients

Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc's Yescarta were still responding to the cell therapy after at least two years of follow-up, the company said on Sunday.

Yemen sterilizes Sanaa water supplies as cholera outbreak picks up again

Authorities in the Houthi-held Yemeni capital Sanaa are sterilizing water supplies at wells, distribution networks and houses to help stem the world's worst outbreak of cholera.

Cannabis abstinence tied to memory improvement in adolescents, young adults

(Reuters Health) - - Not using cannabis for a month could improve learning ability for adolescents and young adults who used the drug at least weekly, a U.S. study suggests.

Related Videos

Introducing the all-new
Reuters News app

The new Reuters News app is here, redesigned from the ground up to fit your busy life.

Get it now on iOS